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LIDOCAINE 5% MEDICATED PLASTER USE FOR POST-SURGICAL
CRPS TYPE 2
F. Cle`re, C. Dufre`ne, M. Perriot, F. Henry. Consultation
Pluridisciplinaire de la Douleur, Centre Hospitalier, Chaˆteauroux,
France
Introduction: After orthopedic surgery, nerve lesions may lead to
neuropathic pain: some patients develop a Complex Regional Pain
Syndrome (CRPS) type 2. When CRPS occurs after a surgery of a
distal joint, patients often present a localized neuropathic pain.
The current guidelines recommend the use of topical lidocaine as
a ﬁrst-line treatment for the management of localized neuropathic
pain.
Objectives: Our purpose is to present our use of a lidocaine 5%
medicated plaster (licensed in France for post-herpetic pain) in the
management of CRPS.
Methods: The cases of 20 patients with CRPS 2 who used the 5%
lidocaine plaster were reviewed in a retrospective study. Patients
were screened with the DN4 questionnaire.
Results: The mean age of our patients was 53 years (range 24–71)
with a ratio of 1:4 men to women. CRPS type 2 occurred after
surgery of the knee (9 patients, 45%), the ankle (4, 20%), the elbow
(1, 5%), the wrist (4, 20%) and the ﬁngers (2, 10%). Allodynia was
found in 11 patients (55%). Associated treatments were tricyclic
antidepressants (20%), gabapentinoïds (35%) and TENS (85%). After
one month of use, 18 patients (90%) had pain relief of 30% and
more, 11 (55%) of 50% and more with the plaster. Two patients
reported no relief. The mean duration of treatment was 8 months
(range 1–15). There were no reports of serious adverse events.
Conclusion: The lidocaine 5% medicated plaster appears to be useful
and safety in the management of the neuropathic component of
CRPS 2.
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ADJUVANT ACUPUNCTURE TREATMENT IMPROVES NEUROPATHIC
PAIN (NP) IN PERIPHERAL NEUROPATHY (PN) AND INDUCES
NEURONAL REGENERATION
S. Schroeder1,2,3, S. Epple´e1,4, A. Bey1, W. Hu1,5, F. Brazkiewicz3,4,6.
1Hamburg Center for Traditional Chinese Medicine, 2Hanse Merkur
Center for Traditional Chinese Medicine, University Hospital
Eppendorf, Hamburg, Germany; 3Neurophysiology, Instituto di Ciencias
Biomedicas Abel Salazar, Porto, Portugal; 4Heidelberg School of Chinese
Medicine, Heidelberg, Germany; 5World Federation of Acupuncture
Societies, Bejing, China; 6Bremen Center for Traditional Chinese
Medicine, Bremen, Germany
Introduction: In spite of available efﬁcient drug treatment for NP in
PN alternative treatment strategies are desirable, because a notable
number of patients report side effects and there are almost no
therapeutic options for neuronal regeneration.
Objectives: We conducted a pilot study to evaluate the effect of
acupuncture on NP and neuronal regeneration as measured by
subjective parameters and Nerve Conduction Studies (NCS).
Methods: 192 patients with PN of an outpatient clinic were
retrospectively evaluated over a period of one year. Follow up
data of NCS had to be available. 38 patients suffered from NP,
medical drugs on a stable dose for one month before and during
the observation period were accepted. 21 patients got 10 adjuvant
acupuncture treatments on a weekly basis, while 17 control patients
got no additional therapy.
Results: The comparison of the mean individual changes of NCS
during the observation period is shown in table 1.
Table 1: Mean individual change of NCS
Acupuncture
(n =21)
Control
(n = 17)
Difference Unpaired
t-test
Sural nerve amplitude (mV) 1.381±1.457 0.059±2.142 1.322 p=0.0301
Sural nerve conduction (m/s) 9.024±16.412 −1.529±7.916 10.553 p=0.0203
Tibial nerve amplitude (mV) 1.738±2.354 −0.588±1.523 2.326 p=0.0012
Tibial nerve conduction (m/s) 0.833±3.568 −0.588±1.406 1.421 n.s.
Subjective outcome is shown in ﬁgure 1 (X2 = 4.3, df = 2, p = 0.001)
and outcome assessed by NCS is shown in ﬁgure 2 (X2 = 13.8, df = 2,
p = 0.001).
Left: Neuropathic pain – subjective results. Right: Outcome assessed
by NCS.
Conclusions: The data suggest that acupuncture offers an additional
option for the treatment of NP in PN. Improvement of NCS are
considered to be signs of neural regeneration, increased blood ﬂow
to the vasa nervorum and dependant capillaries may contribute to
nerve repair. Acupuncture might induce a long term therapeutic
effect on NP in PN without side effects. Further randomized
controlled trials are necessary.
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PROGRESS TOWARDS A PHASE 1/2 TRIAL OF HSV-MEDIATED
GENE TRANSFER OF GAD IN PATIENTS WITH PAINFUL DIABETIC
NEUROPATHY
D. Wolfe1, M. Mata2, D. Fink2. 1Diamyd, Pittsburgh, PA, 2Neurology,
University of Michigan, Ann Arbor, MI, USA
Introduction: The development of novel effective treatments for
chronic pain has been disappointingly slow. In part this is because
the conservative use of a limited repertoire of neurotransmitters,
receptors and ion channels at multiple sites and in many converging
and diverging pathways serving different functions in the nervous
system that limits the ability to use systemically administered small
molecules to selectively interrupt nociceptive neurotransmission.
Objectives: To overcome this limitation we have constructed a
series of non-replicating herpes simplex virus (HSV)-based vectors
that delivered by inoculation in to the skin efﬁciently target gene
delivery to dorsal root ganglia neurons to effect the release of
antinociceptive neurotransmitters from afferent DRG terminals in a
regionally restricted manner in the dorsal horn of spinal cord.
Methods: We constructed a replication defective HSV vector vG
to express GAD67. In animal studies we found that subcutaneous
inoculation of the vector resulted in a substantial and signiﬁcant
reduction in pain-related behaviors in rodent models of traumatic
(spinal nerve ligation) and diabetic neuropathic pain.
Results: A clinical trial of HSV-mediated transfer of pre-
proenkephalin in patients with cancer pain is underway. A proposal
to test the effect of vG in patients with painful diabetic neuropathy
has been reviewed by the Recombinant DNA Advisory Committee
of the NIH and construction and validation of the human-grade
GAD-expressing HSV vector is underway.
Conclusions: HSV-mediated gene transfer may provide an
additional approach to treat patients with otherwise untreatable
neuropathic pain.
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RETEROSPECTIVE CASE STUDY SERIES: INTRAVENOUS LIDOCAINE
INFUSION FOR PELVIC NEUROPATHIC PAIN MANAGEMENT
A. Gupta, A. Valovska. Department of Anesthesiology, Harvard
Medical School Brigham and Women’s Hospital, Boston, MA, USA
Introduction: Lidocaine has been shown to reduce pain scores
for painful diabetic neuropathy along with mexiletine in painful
